Journal
ACS SENSORS
Volume 3, Issue 9, Pages 1838-1845Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acssensors.8b00631
Keywords
biosensor; optical sensor; protein; nanocarbon; nanomedicine; prostatic carcinoma
Funding
- NIH New Innovator Award [DP2-HD075698]
- NIH Cancer Center Support Grant [P30 CA008748]
- National Science Foundation CAREER Award [1752506]
- Honorable Tina Brozman Foundation for Ovarian Cancer Research
- American Cancer Society
- Pershing Square Sohn Cancer Research Alliance
- Expect Miracles Foundation - Financial Services Against Cancer
- Louis V. Gerstner Jr. Young Investigator's Fund
- Frank A. Howard Scholars Program
- Alan and Sandra Gerry Metastasis Research Initiative
- Center for Molecular Imaging and Nanotechnology at Memorial Sloan Kettering Cancer Center
- Cycle for Survival
- Anna Fuller Fund
- Commonwealth Foundation for Cancer Research
- Imaging and Radiation Sciences Program
- Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center
- Ovarian Cancer Research Fund [370463]
- American Heart Association [17POST33650043]
- NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Therapeutic outcomes in patients with prostate cancer are hindered by the inability to discern indolent versus aggressive disease. To address this problem, we developed a quantitative fluorescent nanosensor for the cancer biomarker urokinase plasminogen activator (uPA). We used the unique fluorescent characteristics of single-walled carbon nanotubes (SWCNT) to engineer an optical sensor that responds to uPA via optical bandgap modulation in complex protein environments. The sensing characteristics of this construct were modulated by passivation of the hydrophobic SWCNT surface with bovine serum albumin (BSA). The sensor enabled quantitative detection of known uPA concentrations in human blood products. These experiments potentiate future use of this technology as a rapid, point-of-care sensor for biomarker measurements in patient fluid samples. We expect that further work will develop a method to discern aggressive vs indolent prostate cancer and reduce overtreatment of this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available